Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE with or without S-1 for BCLC B hepatocellular carcinoma
ChiCTR-TCH-13004755Phase 4Completed
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tegafur-gimeracil-oteracil in hepatocellular carcinoma (HCC) (2 arms), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoints: Time to progression and Disease control rate. Started Sep 2014; status: completed.
02
Drugs
tegafur-gimeracil-oteracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TCH-13004755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TCH-13004755.